Skip to main content


Volume 458: debated on Monday 12 March 2007

To ask the Secretary of State for Health if she will bring forward proposals to use dexrazoxane for the prevention of cardiac damage caused by antibiotics. (116838)

A marketing authorisation for Cardioxane (dexrazoxane) was approved in the United Kingdom in July 2006, initially to Chiron Corporation Ltd. The current marketing authorisation is held by Novartis Pharmaceuticals UK Ltd following a change of ownership application, completed in September 2006.

Cardioxane is authorised for prevention of chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin (anthracycline antibiotics) use in advanced and/or metastatic cancer patients after previous anthracycline containing treatment.